Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Humans
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bortezomib
/ therapeutic use
Dexamethasone
/ therapeutic use
Hematopoietic Stem Cell Mobilization
/ methods
Heterocyclic Compounds
/ therapeutic use
Lenalidomide
/ therapeutic use
Multiple Myeloma
/ drug therapy
Peripheral Blood Stem Cell Transplantation
Transplantation, Autologous
Elotuzumab
Isatuximab
Lenalidomide
Multiple myeloma
Stem cell mobilization
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
24
07
2023
accepted:
10
10
2023
medline:
23
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis aims to evaluate the effects of prolonged lenalidomide induction and isatuximab- or elotuzumab-containing quadruplet induction therapies on PBSC mobilization and collection. A total of 179 transplant-eligible patients with newly diagnosed MM treated at a single academic center were included. The patients were evaluated based on PBSC mobilization and collection parameters, including overall collection results, CD34 The patients' characteristics were well balanced across the different groups. Collection failures, defined as the inability to collect three sufficient PBSC transplants, were rare (n = 3, 2%), with no occurrences in the isatuximab-RVd and elotuzumab-RVd groups. Intensified induction with six 21-day cycles of RVd did not negatively impact the overall number of collected PBSCs (9.7 × 10 This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. Patients were treated within the randomized phase III clinical trials GMMG-HD6 (NCT02495922, 24/06/2015) and GMMG-HD7 (NCT03617731, 24/07/2018). However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed.
Sections du résumé
BACKGROUND
BACKGROUND
While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis aims to evaluate the effects of prolonged lenalidomide induction and isatuximab- or elotuzumab-containing quadruplet induction therapies on PBSC mobilization and collection.
METHODS
METHODS
A total of 179 transplant-eligible patients with newly diagnosed MM treated at a single academic center were included. The patients were evaluated based on PBSC mobilization and collection parameters, including overall collection results, CD34
RESULTS
RESULTS
The patients' characteristics were well balanced across the different groups. Collection failures, defined as the inability to collect three sufficient PBSC transplants, were rare (n = 3, 2%), with no occurrences in the isatuximab-RVd and elotuzumab-RVd groups. Intensified induction with six 21-day cycles of RVd did not negatively impact the overall number of collected PBSCs (9.7 × 10
CONCLUSIONS
CONCLUSIONS
This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy.
TRIAL REGISTRATION
BACKGROUND
Patients were treated within the randomized phase III clinical trials GMMG-HD6 (NCT02495922, 24/06/2015) and GMMG-HD7 (NCT03617731, 24/07/2018). However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed.
Identifiants
pubmed: 37990162
doi: 10.1186/s12885-023-11507-9
pii: 10.1186/s12885-023-11507-9
pmc: PMC10664363
doi:
Substances chimiques
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
elotuzumab
1351PE5UGS
Heterocyclic Compounds
0
isatuximab
R30772KCU0
Lenalidomide
F0P408N6V4
Banques de données
ClinicalTrials.gov
['NCT03617731', 'NCT02495922']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1132Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 1996 Jul 11;335(2):91-7
pubmed: 8649495
Bone Marrow Transplant. 2001 May;27(9):925-31
pubmed: 11436102
Front Immunol. 2020 Aug 14;11:1771
pubmed: 32922390
Cytometry B Clin Cytom. 2021 Jul;100(4):497-508
pubmed: 33017079
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
N Engl J Med. 2003 Dec 25;349(26):2495-502
pubmed: 14695409
Leuk Lymphoma. 2019 Sep;60(9):2199-2206
pubmed: 30845862
Ann Oncol. 2021 Mar;32(3):309-322
pubmed: 33549387
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Leuk Lymphoma. 2013 Oct;54(10):2200-4
pubmed: 23387937
Biol Blood Marrow Transplant. 2018 Jun;24(6):1281-1288
pubmed: 29353110
Bone Marrow Transplant. 2021 Feb;56(2):395-399
pubmed: 32796951
Transfusion. 2017 Oct;57(10):2366-2372
pubmed: 28681435
Lancet Haematol. 2020 Jun;7(6):e456-e468
pubmed: 32359506
Transplant Cell Ther. 2021 Oct;27(10):876.e1-876.e11
pubmed: 34214737
Support Care Cancer. 2013 Sep;21(9):2437-42
pubmed: 23591714
Haematologica. 2021 Aug 01;106(8):2257-2260
pubmed: 33657786
Biol Blood Marrow Transplant. 2013 May;19(5):760-6
pubmed: 23298856
Transplant Cell Ther. 2021 Aug;27(8):661.e1-661.e6
pubmed: 33895403
Haematologica. 2023 Feb 01;108(2):610-614
pubmed: 36200424
Eur J Haematol. 2015 Jan;94(1):12-22
pubmed: 24797118
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Transfus Apher Sci. 2009 Aug;41(1):33-7
pubmed: 19540167
Blood Cancer J. 2020 Sep 4;10(9):91
pubmed: 32887873
Chem Immunol. 2000;75:169-88
pubmed: 10851784
Transfus Med Hemother. 2023 Mar 24;50(5):371-381
pubmed: 37936633
Leukemia. 2007 Sep;21(9):2035-42
pubmed: 17581613
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
Lancet Haematol. 2021 Jan;8(1):e45-e54
pubmed: 33357482
J Clin Oncol. 2010 Dec 10;28(35):e741-3; author reply e744-5
pubmed: 21060027
Lancet Haematol. 2022 Nov;9(11):e810-e821
pubmed: 36328040
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10
pubmed: 36494017
Biol Blood Marrow Transplant. 2010 Apr;16(4):490-9
pubmed: 19925876
Biol Blood Marrow Transplant. 2013 Mar;19(3):445-9
pubmed: 23186983
N Engl J Med. 2003 May 8;348(19):1875-83
pubmed: 12736280